Aldeyra Therapeutics Reaches Agreement with the US Food and Drug Administration for the Use of RASP as an Objective Sign for the Treatment of Dry Eye Disease
Stock Information for Aldeyra Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.